The interesting development for this company is that David Williams has changed the focus from being an early stage cancer test developer in to a research platform company.

The EXO-NET technology which allows the collection of exosomes is key to isolating the biomarkers associated with the specific cancer.

The company is providing the technology to academics and pharma companies with a view to expanding sales and royalties on innovative tests and therapeutics.

Early stage but plenty of potential. SP is well down from my buy in RL.

Today's announcement is classic DW "WEAPONISING EXOSOMES FOR BREAST CANCER TREATMENT".

CSO Prof Gregory Rice said: “INOVIQ’s team has delivered significant progress in the complex task of successfully developing a robust and reproducible CAR-exosome production process. The results obtained in this POC are impressive, comparing very favourably with previously published data. I believe that further enhancement of cancer killing activity is realistically achievable. INOVIQ has established its CAR-exosome platform and is well placed to deliver in vivo data on the anti-tumour efficacy of its CAR-NK-exosome breast cancer therapeutic in CY25.”